Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Go back to Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 6.00 +0.20 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.80 | 52 Week High | $18.00 | |||
| Open | $5.86 | 52 Week Low | $6.91 | |||
| Day High | $6.06 | P/E | N/A | |||
| Day Low | $5.83 | EPS | $-0.67 | |||
| Volume | 878,848 | |||||
